Athersys, Inc / New
Formerly BTHC VI, Inc
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2023 | $4 M | No. 2 | $2 to $10 million | options | SEC | |
| Mar 2012 | $9 M | No. 1 | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Athersys, Inc / New chose not to state its revenue in its newest notice of a funding round (May 2023).
SEC Form D · May 2023
The industry group it chose in its notices: Biotechnology.
SEC Form D · May 2023
That is all the official record says: Athersys, Inc / New has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.
Investors#
No investor of Athersys, Inc / New is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 20 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Daniel Camardo | Executive officer | May 2023 |
| Kasey Rosado | Executive officer | May 2023 |
| Maia Hansen | Executive officer | May 2023 |
| Gil Van Bokkelen | Chairman of the Board of Directors and Chief Executive Officer | Mar 2012 |
| John J. Harrington | Executive Vice President, Chief Scientific Officer and Director | Mar 2012 |
| Laura K. Campbell | Vice President, Finance | Mar 2012 |
| William L. Lehmann | President, Chief Operating Officer and Secretary | Mar 2012 |
| Daniel Camardo | Director | May 2023 |
| Ismail Kola | Director | May 2023 |
| Jack Wyszomierski | Director | May 2023 |
| Jane Wasman | Director | May 2023 |
| Joseph Nolan | Director | May 2023 |
| George M. Milne | Director | Mar 2012 |
| Gil Van Bokkelen | Chairman of the Board of Directors and Chief Executive Officer | Mar 2012 |
| Ismail E. Kola | Director | Mar 2012 |
| Jack L. Wyszomlerski | Director | Mar 2012 |
| John J. Harrington | Executive Vice President, Chief Scientific Officer and Director | Mar 2012 |
| Lee E. Babiss | Director | Mar 2012 |
| Lorin J. Randall | Director | Mar 2012 |
About
Biotechnology company in Cleveland, United States.